In this article we have attempted to review the current pharmacological treatment options for infants with meconium aspiration syndrome with or without persistent pulmonary hypertension. These treatments include ventilatory support, surfactant treatment and inhaled nitric oxide (INO), in addition to older and newer pharmacological treatments. These include sedatives, muscle relaxants, alkali infusion, antibiotics and the newer vasodilators. Many aspects of treatment, including ventilatory care, surfactant treatment and the use of INO, are reviewed in great detail in this issue. On the other hand, many newer pharmacological modalities of treatment described here have not been evaluated with randomized control trials. We have given an overview of these emerging therapies.
Introduction
Meconium aspiration syndrome (MAS) is defined as the presence of respiratory distress and hypoxemia associated with the presence of meconium during or just before delivery. Meconium-stained amniotic fluid is a relatively common occurrence seen in approximately 10 to 15% of deliveries and approximately 5% of these develop true MAS. 1 The most severe cases require assisted ventilation for greater than 48 h and are often associated with persistent pulmonary hypertension. Several recent publications and other reviews in this issue have described in detail the pathophysiology and different aspects of the management. Our goal is to review the pharmacological management of MAS.
Treatment strategies: the past, present and future Various treatment modalities including intrapartum (perineal) and post-delivery oral suctioning were the routine until recently but two recent randomized controlled trials (RCTs) have shown that none of these techniques have decreased the incidence of MAS. 2, 3 These approaches are well covered by different authors in this special issue. We will focus primarily on different treatments in the management of infants admitted to neonatal intensive care unit with moderate-to-severe MAS. Figure 1 shows the schema of our presentation.
The treatment options can be divided into general or specific. The general treatment options are the optimization of ventilation, sedation and alkalanization. The more specific pharmacological therapies are aimed at reducing hypoxia with the use of pulmonary vasodilators (inhaled nitric oxide (INO), oral sildenafil and bosentan), and the lung injury by anti-inflammatory agents, surfactant lavage or replacement.
General management
In all newborns with evidence of severe respiratory distress handling is minimized to prevent worsening of gas exchange due to agitation. Sedation and analgesia are used frequently in infants with MAS and persistent pulmonary hypertension to alleviate pain and discomfort that may lead to hypoxia and right-to-left shunting. Opioids particularly morphine or fentanyl with midazolam are frequently used across the world (77 to 100%). Major side effects of these medications include hypotension, urinary retention, development of tolerance and withdrawal symptoms. Opioids can be given either intermittently or as a continuous drip. Pharmacokinetics and metabolism of these drugs are well studied 4, 5 but their impact on long-term outcome has not been reported in term infants. Infact, no RCTs are available in term infants to support its routine use.
Muscle relaxants
Prior to 2000, depolarizing muscle relaxants were widely used along with opioids to decrease agitation and subsequent hypoxic episodes in ventilated infants. Pancuronium and Vecuronium (0.1 mg kg À1 h
À1
) are the two most commonly used muscle relaxants in neonatal intensive care unit. The benefits of neuromuscular blockade include improved oxygenation, decreased oxygen consumption and decreased accidental extubations. However, a prospective multicenter observational study by Walsh-Sukys et al. 6 showed considerable variations in muscle relaxant use between centers (33 to 98%). Use of muscle relaxants was also associated with increased mortality (Odds ratio: 1.95, confidence interval: 0. 74, 5.18) . In their series, 41% (total N ¼ 385) of the cases had MAS as the primary diagnosis. The side effects of nondepolarizing agents include cardiovascular effects from histamine release, though this is less common in neonates and also tachycardia (vagolytic effect). Neuromuscular blockade can also mask seizures especially in infants depressed at birth. No randomized control studies are available at this time.
Neonatologists are urged to consider the risks and benefits of neuromuscular blockade prior to their use.
Alkalinization
Increasing the pH from 7.45 to 7.5 either by hyperventilation or by sodium bicarbonate infusion has been shown to produce pulmonary vasodilatation both in animal models and human newborns. 7, 8 However, both hyperventilation and sodium bicarbonate infusion should be used with caution in newborns due to their adverse effects on cerebral and coronary circulation. 9, 10 Sodium bicarbonate infusion can increase intracellular acidosis and worsen myocardial perfusion and cardiac output. Hyperventilation may also increase barotrauma and volutrauma, and increase the risk for chronic lung disease. 11 Hypocarbia below 25 mm Hg can also result in hearing loss secondary to injury to hair cells. 10 Walsh-Sukys et al. 6 reported an increased need for extracoporeal membrane oxygenation (ECMO) and oxygen at 28 days in patients treated with sodium bicarbonate. Neither hyperventilation nor alkali infusion have been vigorously tested in a RCT. Fortunately their use seems to be on the decline since the availability of INO.
Initial management has also traditionally included inotropic support to assist cardiac function against suprasystemic pulmonary pressures. Once again, there is no randomized study to support this practice. Drummond et al. 8 were able to show in a case series that dopamine infusion along with tolazoline and hyperventilation helped reduce pulmonary pressure. The combination of tolazoline and dopamine had a variable and unpredictable effect on oxygenation. It is noted that these drugs were not studied independently of each other. Hypotension is frequently secondary to heavy sedation and the use of high mean airway pressure. Dopamine and dobutamine are the two most frequently used inotropes in neonates. High doses of dopamine (>10 mg kg À1 min À1 ) on its own can also contribute to pulmonary vasoconstriction. 12 
Pulmonary vasodilators
Regulation of pulmonary vascular tone is a dynamic process and depends on the balance between various endogenous constrictors (endothelin and thrombaxane) and dilators (nitric oxide (NO) and prostaglandins). Majority of these substances are produced by the pulmonary endothelium. In addition, arterial oxygen and carbon dioxide tension, and lung volume play a major role in the regulation of pulmonary vascular tone. Pulmonary hypertension in patients with MAS is secondary to hypoxia, acidosis, release of the inflammatory mediators and alveolar atelectasis. Thus the pulmonary hypertension of MAS should ideally be treated with adequate ventilation and pulmonary vasodilators. The problem until recently was the inability to find such a truly selective pulmonary vasodilator. We will briefly review the past and present pulmonary vasodilators used in MAS. Table 1 shows dosages of various pulmonary vasodilators used in pulmonary hypertension.
Tolazoline
Tolazoline is a nonspecific vasodilator, which had been used for the treatment of pulmonary hypertension at least two decades before the introduction of INO. Lee and Hox 31 showed that tolazoline led to pulmonary vasodilatation even in the absence of endothelium. Whereas Curtis et al. 32 showed in the animal model that the vasodilatation produced was independent of NO production. Its mechanism of action is directly on the vascular 
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smooth muscle through direct a-adrenergic antagonistic action. Tolazoline can be given intravenously as well as by intratracheal route. 33, 34 There is still no consensus on the dose of tolazoline at which pulmonary vasodilatation can be maximized while eliminating the severe systemic hypotension. Severe systemic hypotension is the most common and severe adverse effect. The drug is currently not available in the United States and is not recommended for the treatment of MAS with pulmonary hypertension.
INO
An ideal pulmonary vasodilator should (a) decrease pulmonary vascular resistance but not systemic vascular resistance, (b) rapidly relieve hypoxia, acidosis and vasoconstriction, (c) have no or minimal systemic effects and (d) be rapidly metabolized or cleared from the body. INO is a good example of such a drug. Indications and dose of INO are discussed elsewhere in this issue.
Phosphodiesterase inhibitors
Phosphodiesterases (PDEs) are a family of enzymes that hydrolyze cyclic nucleotides and regulate their intracellular level. Both cyclic adenosine monophosphate and cyclic guanosine monophosphate play a crucial role in cell signaling. They are classified based on their substrate specificities, pharmacological properties and distribution in the body. PDE inhibitors block the hydrolysis of cyclic nucleotides and thus increase intracellular accumulation of cyclic adenosine monophosphate or cyclic guanosine monophosphate. A brief review of the PDEs' inhibitors is given below.
Several of these agents are being used in adults with severe pulmonary arterial hypertension. Milrinone, dipyridamole, zaprinast and sildenafil (Viagra) have all been used in newborns but the number of patients treated so far are few and no large control studies are available to date.
Milrinone. Milrinone is a PDE-3-specific inhibitor and is one of the earliest drugs studied in newborns. It acts synergistically with INO inducing pulmonary vasodilatation, but in addition it is also a systemic vasodilator and has positive myocardial inotropic activity. It is frequently used in newborns, pediatric and adult patients following cardiac surgery. Inhaled milrinone has been tried in adults with pulmonary hypertension undergoing cardiac surgery. In a recent case report, milrinone was successfully used in four infants who failed to respond to INO. 35 Pharmacokinetics of milrinone have not been studied in newborns. Milrinone may have limited role with the advent of more specific PDE-5 inhibitors, for example, sildenafil.
Dipyridamole. Dipyridamole is a selective PDE-5 inhibitor. In experimental models it has been shown to augment and prolong the response of NO in post-cardiac surgery patients. 36 However, augmentation response is not consistent and in some pediatric studies decrease in pulmonary vascular resistance of >20% is noted in only half the treated cases. Dipyridamole has been shown to help in attenuating the rebound phenomenon seen after discontinuation of INO therapy in pediatric patients. 18, 19 Dosage of dipyridamole ranged from 0.3 to 0.6 mg kg À1 .
18-21
Zaprinast. Zaprinast is a more selective inhibitor of PDE-5 and was one of the original inhibitors studied along with dipyridamole. Intravenous administration showed, in a fetal lamb model, to decrease pulmonary arterial resistance as well as a potentiation of inhaled NO-mediated pulmonary vasodilatation. [36] [37] [38] The concern with intravenous administration was that at moderate-to-high doses systemic vasodilatation was noted. Aerosolized drug therapy has been shown to have less systemic side effects, preferential delivery to better ventilated areas of the lungs and a potentiation of the INO effect. 39, 40 Sildenafil. The most specific PDE-5 inhibitor currently available is sildenafil. It is becoming increasingly popular in the treatment of pulmonary hypertension, especially in post-cardiac surgery cases. 41 Initial success has been noted in some pediatric cases in attenuation of INO-rebound pulmonary hypertension. 42 Baquero et al., 27 in a proof-of-concept, randomized masked study showed an improvement in oxygenation index and pulse oxygen saturation within 6 to 30 h, and significant increase in survival rate (85%, 6/7 infants) in those randomized to receive oral sildenafil. In the placebo group only 1/6 (16%) survived. The dose of sildenafil was 1 mg kg À1 every 6 h till oxygenation index decreased Abbreviations: ET, endotracheal; IV, intravenous; GA, gestational age; NEB, nebulized; PO, per oral; UVC, through umbilical vein catheter.
See the text for details on each drug.
Pharmacotherapy for MAS
A Asad and R Bhat to <20. Pharmacokinetics and bioavailability of orally administered sildenafil has not been studied so far in neonates. A recent report by Martell et al. 43 have shown a significant drop in pulmonary pressures within 2 min following intratracheal administration of 0.75 or 1.5 mg kg À1 dose of sildenafil in piglets with meconium aspiration. Inotropic support was needed to maintain systemic blood pressure. A multicenter study with a large sample size is needed to assess the safety and efficacy of intravenous, oral or intratracheal sildenafil with or without INO.
Oral sildenafil can be a lifesaving drug in the developing countries to treat pulmonary hypertension and also for infants with severe hypoxia and respiratory failure in community hospitals prior to their transfer to a tertiary care center. Both dipyridamole and sildenafil have been approved for clinical use in adults with pulmonary hypertension.
Prostaglandins and prostacyclins
It has been known that both the fetal and neonatal pulmonary vascular bed is sensitive to the arachidonic acid metabolites. Prostaglandin E1 (PGE1) has been in clinical use for more than three decades for maintaining ductal patency, but it is a weak pulmonary vasodilator when compared with prostacyclin (PGI2).
44
PGI2 has been in use to treat adult pulmonary hypertension for several years and is the first drug to be approved for clinical use. It is a potent pulmonary and systemic vasodilator, and its action is mediated through increased cyclic adenosine monophosphate. It has antiproliferative and antiplatelet adhesion effects. The major drawback of PGI2 is the need for long-term intravenous infusion and its very short half-life. Various synthetic analogs of PGI2, namely treprostinil, iloprost and beraprost, are in clinical use in adults because of their longer half-life and ease of administration, either orally or as aerosol and subcutaneous drip. Aerosolized PGI2 has been tried in newborns who failed to respond to INO. 45 Another prostaglandin, PGD2 has been evaluated in newborns with pulmonary hypertension but is yet to show any clinical benefit. 46 Endothelin antagonists Endothelins are vasoconstrictors derived from the endothelial cells. Of the two major types of endothelins, ET-1 mediates vasoconstriction and smooth muscle cell proliferation through ET-A receptors. ET-A receptors have been found on smooth muscle cells in pulmonary arteries. 47 Endothelins are involved in maintaining the pulmonary vascular tone in the neonatal period. Recent studies have reported elevated ET-1 level 48 and an upregulation of ET-1 gene expression in the pulmonary vasculature following MAS. 22, 49 In adults with pulmonary hypertension, the combined ET-A and ET-B receptor antagonist bosentan has been used successfully. 50, 51 In pediatric and neonatal populations information is limited to case reports. The drug is currently available only in oral formulation, which may hinder its use in critically ill newborns. Bosentan is approved by the FDA for pulmonary hypertension in adults. Side effects of the drug include abnormal liver enzymes. Second-generation ET-A blockers such as tezosentan and sitaxsentan are being studied both in animal models and in adults with pulmonary hypertension and/or heart failure at this time.
29,52
Adenosine ATP is a purine nucleotide and well-known dilator of systemic and pulmonary vasculature in both fetal and neonatal vessels. 53 ATP causes vasodilatation by acting on endothelial A2 adenosine receptors and subsequent release of NO. Its use in a meconium lung was studied by Kappa et al. 53 in the porcine model and he showed that at low doses it was able to cause an amelioration of the pulmonary hypertension. However, withdrawal of ATP led to significant rebound and even an overshoot phenomenon.
From a randomized placebo-controlled trial of 18 infants, Konduri et al. 30 showed an improvement in oxygenation only in 4/9 (45%) term infants with persistent pulmonary hypertension. The dosage used was 25 to 50 mg kg À1 min À1 and no systemic side effects were observed. It did not decrease the need for ECMO, bronchopulmonary dysplasia or mortality. Adenosine does have a short half-life and rapid metabolism, therefore it should be given through the umbilical venous line directly to right atrium to reach the pulmonary artery.
Magnesium sulfate
Magnesium at high doses is a smooth muscle relaxant and vasodilator. It acts by antagonizing calcium entry in to smooth muscle cells. Wu et al. have shown that it also suppresses catecholamine release and alters metabolism of prostaglandins and responsiveness of smooth muscles to vasopressors. 54 Owing to its varying modes and site of action, it is a relatively nonspecific vasodilator with a significant risk for systemic hypotension. 55, 56 However, in clinical trials in children who have failed conventional therapies, significant improvement has been shown in both oxygenation and oxygenation index without significant hypotension. 16, 56 Magnesium sulfate also has sedative and antithrombotic activities. In third world countries where INO is not easily available, this multifaceted drug can be used to alleviate hypoxia. RCTs have not been done so far. Table 2 shows some of the newer pulmonary vasodilators currently undergoing investigation. Pharmacotherapy for MASArginine L-arginine infusion is being studied as an adjunct for NO as well as for its potential use in the weaning process. L-arginine is a required substrate for NO synthesis and under oxidative stress conditions it increases the activity of nitric oxide synthase. 57 It also helps to preserve endogenous nitric oxide synthase activity thus has potential for helping in the weaning of NO. RCTs of L-arginine in persistent pulmonary hypertension are still lacking.
Future pulmonary vasodilators

Superoxide dismutase
Superoxide dismuatse is an endogenous scavenger and potent anti-inflammatory and anti-oxidative enzyme. There is now a recombinant version (rhSOD) that is commercially available. The rhSOD is being studied as an adjunct with INO therapy. Steinhorn et al. 58 initially showed how single dose administration of rhSOD in a lamb model with and without INO led to selective pulmonary vasodilatation. In view of these anti-inflammatory and pulmonary vasodilator effects, rhSOD appears to be an exciting new addition to treat pulmonary hypertension in MAS.
Other drugs Surfactant. Meconium contents are highly viscous and consist of desquamated epithelial cells and inspissated intestinal secretions. The large glycoproteins in meconium cause increased adhesiveness. 59 Rubin et al. 60 in 1996 reported that the mucociliary transportability of meconium was lower than that of sputum clearance in cystic fibrosis patients. Meconium constituents especially the fatty acids and other soluble proteins and bilirubin are direct inhibitors of surfactant. 61, 62 Two small randomized control studies have reported significant improvement in oxygenation and decrease in barotrauma with surfactant treatment. 63, 64 Readers are referred to excellent reviews on surfactant therapy and lavage in meconium aspiration in this issue.
Antibiotics
The use of antibiotics in MAS has been controversial. Initial use was advocated as it was believed that stress caused the passage of meconium and the most likely reason for perinatal stress was an infection, hence the need to treat with antibiotics. This was substantiated in 1967 when Bryan 65 showed that sterile meconium was never fatal on its own, but when given intratracheally along with Escherichia coli it reduced the number of organisms needed to cause death. A more recent in vitro study by Eidelman et al. 66 showed once again that clear amniotic fluid was inhibitory for bacterial growth but in the presence of meconium b-Streptococci grew at much faster rate. It is still controversial whether every infant with meconium aspiration needs antibiotic therapy. Few prospective RCTs are available from outside the United States for comparison of antibiotic use. In a prospective RCT of non-ventilated infants Lin et al. 67 showed that antibiotic treatment did not alter duration of tachypnea, oxygen support and the need for nasal continuous positive airway pressure between the treated and untreated infants. Of the 306 infants, 2-month follow-up data were available only for 259 infants. None of these infants required ventilator support and none had perinatal risk factors. The use of antibiotics gave no advantage in terms of oxygen supplementation, severity of respiratory distress or mortality. Two other prospective studies from Shankar et al. 68 and Krishnan et al. 69 from India also concluded that routine post-natal antibiotic therapy is of no benefit. These studies do support the current view that routine antibiotic therapy in MAS does not alter clinical course. Currently in our unit only infants admitted with MAS requiring ventilatory support or infants admitted with risk factors (prolonged rupture of membranes, chorioamnionitis or positive antenatal group B beta streptococcus screen) receive antibiotics after obtaining initial cultures.
Anti-inflammatory agents Steroids. Although the initial phase of deterioration in the lung mechanics is because of the mechanical obstruction and surfactant inactivation, the persistence of the dysfunction is thought to be because of activation of the inflammatory cascade. Chemical pneumonitis is the second cardinal finding in MAS. Khan et al. 70 in 2002 showed histological and biochemical evidence of meconium-induced airway dysfunction in a murine model. Our own animal studies in newborn rabbits following tracheal instillation of meconium showed significant increase in several cytokines namely TNFa, IL-8 and IL-1b in tracheal aspirate. 71 This was associated with significant apoptosis. 72 As inflammation is one of the major findings in MAS; several investigators have attempted to treat MAS with steroids. Steroids are potent antiinflammatory medications. Glucocorticoids, particularly dexamethasone, has been shown to improve oxygenation and lung function in animal models of MAS 73 and in at least one uncontrolled study of human newborns with MAS. 74 A recent Cochrane review 75 found two small RCTs (a 3rd study was unpublished) and the meta-analysis of the data showed no differences in mortality, chronic lung disease and length of stay. The major weaknesses in these studies were small sample size and lack of long-term follow-up. Owing to the lack of consistent short-term benefit as well as recent concerns about its long-term outcome, dexamethasone cannot be recommended at this time as an anti-inflammatory agent in MAS.
In summary the recent advances in pharmacological treatment namely INO and surfactant has certainly decreased the need for ECMO in MAS infants. However there is a definite need for further multicenter studies to evaluate some of the specific and nonspecific therapies discussed in this review. As MAS is a major cause of mortality and morbidity in the developing countries, studies focusing on prevention and early treatment should be continued to alleviate this tragedy.
